Drug Trial Radar · NCT04900350
A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Actual
Start
Jun 18, 2021
Primary completion
Sep 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a open label, phase I/II study. All patients are diagnosed with higher-risk MDS, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with higher-risk MDS.
Conditions
- Myelodysplastic Syndrome
Interventions
AK117Drug
Subjects receive AK117 intravenously.
AzacitidineDrug
Subjects receive Azacitidine subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Complete Remission (CR)Time frame: Approximately 6 months
- Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years.
- Duration of Complete Remission (DoCR)Time frame: Up to approximately 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.